According to data from a study by the National Center for Oncological Research (CNIO), which have been published in the journal Proceedings of the National Academy of Sciences (PNAS), the antibodies that block the VEGF protein, which are currently used as an anticancer agent, could be used in the future to treat psoriasis, since they have demonstrated their ability to reduce the symptoms of this skin disease, decreasing the thickness and inflammation of the dermis.
For the trial, the scientists used mice, which showed an increase in VEGF, with excessive formation of blood vessels in the skin. They were given anti-VEGF, and a decrease in the symptoms of psoriasis could be observed, showing almost normal skin, as well as a reduction in the number of blood vessels.
Researchers Helia B. Schonthaler and Erwin Wagner, from the CNIO, explained that the skin of the mice had an epidermal architecture very close to normal, and a smaller number of blood vessels, which were also smaller. Therefore, the possibility of using anti-VEGF antibodies as a new treatment for people with psoriasis.
This research may help not only cancer patients, but also people suffering from psoriasis, because antibodies to block VEGF are being used to treat both types of diseases.